Flow Pharma, Inc.
World Leaders in T-Cell Immunotherapy
Engineering and Manufacturing Medicines that Treat and Prevent Disease via Selective T-Cell Stimulation
Ebola Vaccine Creator
United States Department of Defense Vaccine Contractor
Flow Pharma, Inc. is a Cleveland Ohio based biopharmaceutical company. We utilize artificial intelligence to detect peptide targets on cancer cells and virus-infected cells. We then design, synthesize, and deliver identical peptides to stimulate therapeutic attack by the patient’s native immune system. These revolutionary T-cell stimulating therapeutic peptides can be administered by injection or inhalation to selectively stimulate precision-targeted immune response.
We recently completed pre-clinical testing of FLOVID-20, a COVID-19 immunotherapy, at the United States National Laboratory at the University of Texas in Galveston. The test results demonstrate that FLOVID-20 immunized macaque monkeys, protecting them from COVID-19.
Flow Pharma has created FlowVax Survivin, a breast cancer immuno-therapeutic, targeting a neoantigen found on malignant breast cells. Our initial animal tests demonstrate a favorable response in hormone therapy resistant malignant breast cells (triple negative breast cancer). Our additional cancer therapeutic development targets include HPV-related cancers of the cervix and head & neck.